The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / November / Making Pediatric Leukemia Testing Accessible
Oncology Omics Research and Innovations Precision medicine Molecular Pathology

Making Pediatric Leukemia Testing Accessible

Research into long-read transcriptome sequencing suggests single assays could close the molecular testing gap for pediatric patients

By Helen Bristow 11/18/2026 News 2 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll

Share

5 Key Takeaways
  • 1

    Pediatric leukemia molecular testing often requires multiple costly, time-consuming assays and substantial infrastructure and expertise.

  • 2

    These testing requirements can limit comprehensive diagnostics in low-resource settings, including low- and middle-income countries.

  • 3

    The researchers used long-read nanopore sequencing to generate multimodal leukemia diagnostic data with a low-cost, portable platform.

  • 4

    The MinION platform can multiplex up to 12 samples per flow cell, with estimated consumables costs of about $100 per case.

  • 5

    Further validation is underway to assess concordance, or noninferiority, with standard-of-care diagnostics before broader adoption.

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Helen Bristow

Combining my dual backgrounds in science and communications to bring you compelling content in your speciality.

More Articles by Helen Bristow

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.